Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15%...
Auteurs principaux: | George, A, Riddell, D, Seal, S, Talukdar, S, Mahamdallie, S, Ruark, E, Cloke, V, Slade, I, Kemp, Z, Gore, M, Strydom, A, Banerjee, S, Hanson, H, Rahman, N |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
Nature Research
2016
|
Documents similaires
-
The ICR639 CPG NGS validation series: A resource to assess analytical sensitivity of cancer predisposition gene testing [version 1; referees: 2 approved]
par: Shazia Mahamdallie, et autres
Publié: (2018-06-01) -
Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN.
par: Fowler, A, et autres
Publié: (2016) -
CoverView: a sequence quality evaluation tool for next generation sequencing data [version 1; referees: 2 approved]
par: Márton Münz, et autres
Publié: (2018-04-01) -
The Quality Sequencing Minimum (QSM): providing comprehensive, consistent, transparent next generation sequencing data quality assurance [version 1; referees: 2 approved, 1 approved with reservations]
par: Shazia Mahamdallie, et autres
Publié: (2018-04-01) -
Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN [version 1; referees: 2 approved]
par: Anna Fowler, et autres
Publié: (2016-11-01)